INTRODUCTION
Atrial fibrillation (AF) is the most common form of alteration in cardiac rhythm, with a prevalence of 1-2% in the general population [1] . AF, even in its non-valvular form (NVAF), is associated with more severe episodes of stroke, with a higher degree of residual disability, or associated with increased mortality, particularly in patients aged ≥ 75 years [2] . In Western countries, the annual cost of treatment for patient with AF is estimated to be about € 3,000 [3] , which projected on the Italian population (543,000
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In Italy there are about 200,000 people affected by stroke every year: of these, 40,000 die shortly after and another 40,000 lose completely their self-sufficiency, completely changing their lives and those of their families [4] . It is estimated that 15% of total stroke is attributable to subjects with AF (about 30,000 strokes) [4] . Given these events, the cost to the NHS per stroke is about € 17,500, the annual total cost € 3,500,000,000 for all strokes and € 525,000,000 for those caused by AF [4] . Treatment with oral anticoagulants vitamin K antagonists (VKA) such as warfarin, is nowadays the therapy of choice for stroke prevention in patients with atrial fibrillation [5] . However, the difficulty in maintaining the anticoagulant effect in the therapeutic range greatly limits its effectiveness, increasing the probability of bleeding, as well as representing a contraindication to the prescription of therapy in patients with poor compliance or unable to perform the necessary laboratory checks. In addition, many patients who are administered this therapy, if not followed in specialized centers (TAO -anticoagulation therapy center) may suffer from inadequate anticoagulation [6] . In the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy), dabigatran etexilate has proved effective as warfarin at the lowest dose (110 mg twice daily) and significantly more effective than warfarin at the highest dose (150 mg twice daily) in preventing stroke and systemic embolisms over a two-year period of treatment in patients with atrial fibrillation and risk of stroke [7] .
AIM OF THE STUDY
The study aims to assess the affordability of the use of dabigatran etexilate (DE) for the Italian NHS, in patients with NVAF through a budget impact analysis in a timeframe of 5 years.
METHODS

Scenarios and reference population
The budget impact analysis in a timeframe of 5 years was divided into 3 scenarios: -Scenario 1: current management of patients with NVAF. -Scenario 2: all patients with NVAF treated with VKA. -Scenario 3: all patients with NVAF treated with DE. The population considered is the one with indication for anticoagulation. Therefore, also patients intolerant of VKA and patients with severe renal impairment are included.
Both types of patients are distributed evenly (VKA-treated patients and patients treated with dabigatran etexilate) among the various scenarios, avoiding biases regarding the comparison among the budget impacts.
Assumptions of the analysis
This was an analysis from the Italian NHS perspective: therefore, indirect costs are excluded, although they represent a major economic burden, in the case of warfarin use, both for families and society. Moreover, for estimating the target population of the analysis and the associated costs, the following assumptions are considered: -In Italy, NVAF patients with indication for anticoagulation therapy are 335,000 (Appendix A). -The risk of stroke is 4.5% per year in patients with untreated NVAF [8] . -The reduction in the risk of ischemic stroke associated with the treatment with warfarin, at adjusted dosage in order to achieve INR values between 2 and 3, is 65% [9] . -The incidence of hemorrhagic stroke with warfarin, well controlled, is equal to 0.38 x 100 patients/year [7, 10] . -The average time in therapeutic range (TTR) in Italy for patients treated with VKA is equal to 56.3% [11] . -The odds of ischemic events is 43% in patients treated with warfarin with TTR < 60% [12] . -The average cost of management of acute stroke is equal to 17,500 €/year [4] . -The average cost of managing post-stroke period is equal to 7,600 €/year [13] . -The costs of management of stroke here considered may be conservative, since it is known that the atrial fibrillation-related strokes are generally more severe and disabling [4] . [17] . -The incidence of hemorrhagic stroke with dabigatran etexilate is 0.11 x 100 patients/year in the RE-LY study [7, 10] . In Europe, regulatory authorities recommend the use of dabigatran etexilate 150 mg twice daily for patients younger than 80 years (approximately 55,8% of the total population eligible to treatment) and 110 mg twice daily for patients aged ≥80 years (approximately 55,8% of the total population eligible to treatment). In order to simplify the comparison, it was assumed that: -In every scenario, all patients are treated from the first day of every year, to assess the maximum potential impact of the various costs. -The adherence to the treatment for dabigatran etexilate and warfarin is 95% (728 €/ year and 16,2 €/year, respectively) [7, 10] . -The datum on the time in therapeutic range (2 ≤ INR ≥ 3) used is that for the patients treated for more than 1 year. This is justified by the fact that international and national studies show that, for patients treated for less than 1 year, the TTR is significantly lower than the TTR correlated with a longer duration of anticoagulant treatment, remaining below the average figure of 50% [4, 11] . In fact, as widely recognized by the international scientific community [3] , these patients are at significantly greater risk of developing a stroke than others. On the other hand, the inclusion of this parameter in scenarios 1 and 2 would have lead to a considerable increase in the hypothetical cost of disease management or an advantage in the scenario where dabigatran etexilate is used. It was therefore decided to prefer the simplicity of analysis of the model and not to include this additional parameter.
Sensitivity analysis
Finally, a one-way sensitivity analysis was performed on the costs of monitoring patients on VKA therapy and on the costs of the drug; both parameters, taken into account, are those most affected by a high variability (heterogeneity of monitoring costs), uncertainty (the price of the drug will be determined by AIFA) and impact on the final budget impact result. The minimum (€ 212) and maximum (€ 446) value of the costs of treatment monitoring of patients on VKA therapy was extracted from a research done by ANMDO (2012) in collaboration with the Centro Interdipartimentale di Studi Internazionali sull'Economia e lo Sviluppo (CEIS) at the Faculty of Economics, University of Rome Tor Vergata, and the Centro di Ricerche e Studi in Management Sanitario (CERISMAS) at the Catholic University of Sacro Cuore in Rome. Variations of +/-10% were applied to the cost of the drug.
RESULTS
Scenario 1: current management of patients with NVAF
In the year 1 (2011), 335,000 individuals with NVAF have indication for oral anticoagulation, of whom approximately 183,000 are treated with VKA, while the remaining 152,000 aren't treated with oral anticoagulants. In Table I the current situation versus no treatment is analyzed in terms of events prevented by the current management of disease (year 1). Table II shows the 5-year prediction of ischemic and hemorrhagic strokes in the Italian situation. From Table I it is clear how the current treatment of NVAF involves the reduction of only 2,851 strokes, in the first year of observation, compared with the total number of strokes developed in the scenario of total non-treatment (15, 075) . This confirms that, despite the enormous organizational effort, there is still a major unmet need in the management of NVAF. The underuse of oral anticoagulation, associated with the difficulty in keeping the patients treated with VKA within an acceptable therapeutic range, results in an enormous social and human cost, represented by a total of more than 63,000 strokes cumulated in the 5-year period considered (Table II) .
Starting from the cost assumptions reported in the background when presenting the scenarios, Table III shows the current cost of management of NVAF. Table III shows that the cumulative cost over the 5-year period is over € 2.3 billions and the major cost generator in the management of NVAF is the cost of stroke management (€ 2.03 billions). Indirect costs, burdening families and society, were not considered in this analysis. According to the CENSIS survey, presented in 2011
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at the World Day of stroke, every stroke patient costs about € 30,000 to the family per year [18] . Table IV lists the number of ischemic and hemorrhagic strokes resulting from this scenario, and how many of them would be avoided in comparison with the current situation. Table V shows the prediction of the 5-year period of ischemic and hemorrhagic strokes after treatment with VKA of the entire Italian population with NVAF. In this scenario (Table IV) , the number of strokes avoided per year increases to -5,219 compared to no treatment (-2,368 compared to the current situation), although the number of events remains high (about 10,000 events/ year; Table V) . Starting from the cost assumptions reported in methods section, treatment with VKA, with all the obvious social and health benefits in terms of health "saved". -An increase in the cost of drug treatment, which in this case must be considered as the potential maximal expenditure. -Savings for the NHS at the fifth year of observation of 173 million Euros vs. the current treatment and 123 million Euros vs. treatment with VKA. The savings from the reduction of indirect costs of both society and families of patients with NVAF should be added to all this, resulting in huge direct and indirect savings for the society.
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Scenario 3 vs. scenario 2 Year 1 Year 2 Year 3 Year 4 Year 5
SENSITIVITY ANALYSIS
Cost of monitoring of the patient receiving VKA therapy = € 212
As showed in Table XI an extensive use of dabigatran etexilate would result in: -Also in this situation, a saving for the NHS at the fifth year of observation of 71 million Euros vs. the treatment with VKA (-43% compared to the basal hypothesis). -A reduction of 26,297 in the total number of cumulative strokes vs. the treatment with VKA, with all the obvious social and health benefits in terms of health "saved" (savings in terms of clinical benefit remain unchanged).
Cost of monitoring of the patient receiving VKA therapy € 446
As showed in Table XII , an extensive use of dabigatran etexilate would result in: -A saving for the NHS at the fifth year of observation of 156 million Euros vs. the treatment with VKA (+27% compared to the basal hypothesis). -A reduction of 26,297 in the total number of cumulative strokes vs. the treatment with VKA, with all the obvious social and health benefits in terms of health "saved" (savings in terms of clinical benefit remain unchanged).
Cost of dabigatran etexilate 1.89 €/ day (-10% vs. basal hypothesis)
As showed in Table XIII an extensive use of dabigatran etexilate would result in: -In this situation a saving for the NHS at the fifth year of observation of 149 million Euros vs. the treatment with VKA (+24,6% compared to the basal hypothesis). -A reduction of 26,297 in the total number of cumulative strokes vs. the treatment with VKA, with all the obvious social and health benefits in terms of health "saved" (savings in terms of clinical benefit remain unchanged).
Cost of dabigatran etexilate 2.31 €/ day (+10% vs. basal hypothesis)
As showed in Table XIV an extensive use of dabigatran etexilate would result in : -Also in this situation a saving for the NHS at the fifth year of observation of 96 million Euros vs. the treatment with VKA (-21% compared to the basal hypothesis). -A reduction of 26,297 in the total number of cumulative strokes vs. the treatment with VKA, with all the obvious social and health benefits in terms of health "saved" (savings in terms of clinical benefit remain unchanged).
DISCUSSION
The current treatment of NVAF involves the reduction of only 2,851 strokes, in the first year of observation, compared with the total number of strokes developed in the scenario of total non-treatment (15, 075) . This confirms that, despite the enormous organizational effort, there is still a major unmet need in the management of NVAF. The underuse of oral anticoagulation, associated with the difficulty in keeping the patients treated with VKA within an acceptable therapeutic range, results in an enormous social and human cost, represented by a total of more than 63,000 strokes cumulated in the 5-year period considered (Table II) . The cumulative cost for the current treatment of NVAF over the 5-year period exceeds € 2.3 billions and the major cost generator in NVAF management is stroke management cost (2.03 billions). Indirect costs, burdening families and society, were not considered in this analysis. According to the CENSIS survey, presented in 2011 at the World Day of stroke, every stroke patient costs about € 30,000 to his/her family per year [18] . The number of avoided strokes per year, resulting from the scenario where all NVAF patients are treated with VKA, amounts to 5,219 compared to no treatment (-2,368 compared to the current situation), although the number of events remains high (about 10,000 events/year; Table  V) . Again, as in the previous scenario, the cumulative cost over the 5-year period is over 2 billion Euros (2.294 billion Euros). Similarly to the previous scenarios, starting from the cost assumptions reported in the background, and using a daily cost of dabigatran etexilate equal to 2.10 Euros (the lowest in Europe in May 2012: current price in Spain), an extensive use of dabigatran etexilate would cause: -A reduction of more than 38,500 of the total cumulative number of strokes vs. the current scenario and over 26,297 vs. the treatment with VKA, with all the obvious social and health benefits in terms of health "saved". -An increase in the cost of drug treatment, which in this case must be considered as the potential maximal expenditure. -Savings for the NHS at the fifth year of observation of 173 million Euros vs. the current treatment and 123 million Euros vs. treatment with VKA. The savings from the reduction of indirect costs of both society and families of patients with NVAF should be added to all this, resulting in huge direct and indirect savings for the society. 
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Finally dabigatran etexilate allows significant savings in indirect costs for society and families involved in a debilitating disease such as stroke. These costs are inherently difficult to quantify, yet priceless when considering the socio-emotional impact caused by a stroke, not only for the patient but also for all the relatives involved in this important event.
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